[摘要] 目的 探讨STEMI急诊PCI治疗联用替格瑞洛与11b/111a受体拮抗剂对出血风险的影响。 方法 整群选取2010年1月—2015年5月该医院收治的STEMI患者184例，随机分成观察组(PCI治疗联用替格瑞洛与11b/111a受体拮抗剂)和对照组(PCI治疗联用氯吡格雷与11b/111a受体拮抗剂)各92例，比较两组患者的出血风险。结果 对照组出血风险为3.3%，观察组出血风险为4.4%(P>0.05)。结论 急诊PCI治疗联用替格瑞洛与11b/111a受体拮抗剂不明显增加STEMI患者的出血风险。

 [关键词] STEMI；PCI；替格瑞洛

 [中图分类号] R541 [文献标识码] A [文章编号] 1674-0742(2016)05(a)-0105-02

 [Abstract] Objective To discuss the effect of PCI treatment combined with Ticagrelor and 11b/111a receptor antagonist on hemorrhage risks of patients with STEMI emergency. Methods 184 cases of STEMI patients admitted and treated in our hospital from January 2010 to May 2015 were selected and randomly divided into two groups with 92 cases in each ...... 第 1 2 页 下一页
 百拇医药网 http://www.100md.com/html/paper/1674-0742/2016/13/42.htm
您现在查看是摘要页，全文长 3669 字符。